Posted by Michael Wonder on 18 Nov 2025
FDA approves epcoritamab-bysp for follicular lymphoma indications
18 November 2025 - Today, the FDA approved epcoritamab-bysp (Epkinly, Genmab) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
